Literature DB >> 7530930

Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland.

N J Agnantis1, A E Constantinidou, M Papaevagelou, N Apostolikas.   

Abstract

The present study assessed the immunohistochemical expression of ras p21 oncoprotein in 41 cases of benign and cancerous lesions of the prostate gland and correlated p21 expression with survival of patients operated for prostate cancer. Our results show that p21 is detected in both categories of patients, the expression being weak in adenomatous hyperplasia and more intense in cancer. We were also able to show an inverse relation between ras p21 positivity and the degree of differentiatin. Follow-up study revealed a statistically significant (p < 0.05) correlation between 5 year survival and p21 expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530930

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

2.  Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.

Authors:  Tatyana Isayeva; Lakisha D Moore; Diptiman Chanda; Dongquan Chen; Selvarangan Ponnazhagan
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

3.  Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene.

Authors:  Miljana Tanic; Kira Yanowsky; Cristina Rodriguez-Antona; Raquel Andrés; Iván Márquez-Rodas; Ana Osorio; Javier Benitez; Beatriz Martinez-Delgado
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

4.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.